Sundrug Co.,Ltd.
SDGCFOTCHealthcare● Active
$30.97
+$2.79(+9.90%)
Market Cap$3.6B
P/E Ratio—
52W High$30.97
52W Low$28.18
Sundrug Co.,Ltd. (SDGCF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SDGCF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
$0.39
Est. -$0.87 · +144.2%
Revenue
$1.30B
Est. $1.30B · +0.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
SDGCF reports quarterly as a OTC-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.44 | — | — | — | $1.36B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.87 | $0.39 | +144.2% | $1.30B | $1.30B | +0.2% |
| ▼ Q1 FY2026 | Feb 12, 2026 | $0.53 | $0.49 | -8.0% | $1.39B | $1.40B | -0.8% |
| ▼ Q3 FY2025 | Aug 14, 2025 | $0.48 | $0.47 | -1.4% | $1.43B | $1.44B | -0.5% |
| — Q2 FY2025 | May 15, 2025 | $0.39 | $0.39 | +0.7% | $1.32B | $1.32B | +0.2% |
| ▲ Q1 FY2025 | Feb 14, 2025 | $0.49 | $0.52 | +5.5% | $1.32B | $1.32B | +0.3% |
| ▼ Q4 FY2024 | Nov 14, 2024 | $0.44 | $0.40 | -9.0% | $1.35B | $1.41B | -4.0% |
| ▲ Q3 FY2024 | Aug 14, 2024 | $0.38 | $0.39 | +2.9% | $1.21B | $1.21B | -0.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.44
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
$0.39
EPS Est.
-$0.87
EPS Surpr.
+144.2%
Revenue
$1.30B
Q1 FY2026
Feb 12, 2026Miss
EPS Actual
$0.49
EPS Est.
$0.53
EPS Surpr.
-8.0%
Revenue
$1.39B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
$0.47
EPS Est.
$0.48
EPS Surpr.
-1.4%
Revenue
$1.43B
Q2 FY2025
May 15, 2025
EPS Actual
$0.39
EPS Est.
$0.39
EPS Surpr.
+0.7%
Revenue
$1.32B
Q1 FY2025
Feb 14, 2025Beat
EPS Actual
$0.52
EPS Est.
$0.49
EPS Surpr.
+5.5%
Revenue
$1.32B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
$0.40
EPS Est.
$0.44
EPS Surpr.
-9.0%
Revenue
$1.35B
Q3 FY2024
Aug 14, 2024Beat
EPS Actual
$0.39
EPS Est.
$0.38
EPS Surpr.
+2.9%
Revenue
$1.21B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2027 | $0.41 | $0.41 | $0.43 | 1 |
| Q4 FY2026 | $0.50 | $0.51 | $0.52 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $221B | $225B | $230B | 2 |
| Q4 FY2027 | $233B | $237B | $243B | 3 |
| Q3 FY2027 | $226B | $230B | $235B | 2 |
| Q2 FY2027 | $223B | $227B | $232B | 2 |
| Q1 FY2027 | $219B | $222B | $228B | 3 |
| Q4 FY2026 | $230B | $233B | $239B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +144.2% | $28.18 | $28.18 | +0.00% |
| ▼ Q1 FY2026 | Feb 12, 2026 | -8.0% | $28.18 | $28.18 | +0.00% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -1.4% | $28.18 | $28.18 | +0.00% |
| ▲ Q2 FY2025 | May 15, 2025 | +0.7% | $28.18 | $28.18 | +0.00% |
| ▲ Q1 FY2025 | Feb 14, 2025 | +5.5% | $28.18 | $28.18 | +0.00% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -9.0% | $28.18 | $28.18 | +0.00% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +2.9% | $28.18 | $28.18 | +0.00% |
| ▲ Q2 FY2024 | May 15, 2024 | +3.4% | $28.18 | $28.18 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 15, 2026
EPS Beat/Miss
+144.2%
Price Before
$28.18
Price After
$28.18
Q1 FY2026+0.00%
Report Date
Feb 12, 2026
EPS Beat/Miss
-8.0%
Price Before
$28.18
Price After
$28.18
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
-1.4%
Price Before
$28.18
Price After
$28.18
Q2 FY2025+0.00%
Report Date
May 15, 2025
EPS Beat/Miss
+0.7%
Price Before
$28.18
Price After
$28.18
Q1 FY2025+0.00%
Report Date
Feb 14, 2025
EPS Beat/Miss
+5.5%
Price Before
$28.18
Price After
$28.18
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
-9.0%
Price Before
$28.18
Price After
$28.18
Q3 FY2024+0.00%
Report Date
Aug 14, 2024
EPS Beat/Miss
+2.9%
Price Before
$28.18
Price After
$28.18
Q2 FY2024+0.00%
Report Date
May 15, 2024
EPS Beat/Miss
+3.4%
Price Before
$28.18
Price After
$28.18
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate5 / 8 quarters
Largest Move+0.00% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SDGCF ends December
Sundrug Co.,Ltd. (SDGCF) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $0.39 — beating the analyst consensus of $-0.87 by +144.2%. The next SDGCF earnings date is expected around September 1, 2026.
Each quarter, investors track SDGCF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SDGCF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SDGCF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SDGCF earnings · 5 questionsSundrug Co.,Ltd.'s next earnings report is expected around September 1, 2026. SDGCF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SDGCF historically reports after market close (AMC).
SDGCF earnings datewhen is SDGCF earningsSDGCF next earnings datewhen does SDGCF report earningsSDGCF earnings calendar
▸ Source: FMP · Sundrug Co.,Ltd. SEC filings · US GAAP · Sundrug Co.,Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026